


Press Release

Astellas Ranked First in the Pharmaceutical Sector in the Securities Analysts Association of Japan’s “2026 Award for Excellence in Corporate Disclosure”

TOKYO, October 8, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the company has ranked first in the pharmaceuticals sector for the “2026 Award for Excellence in Corporate Disclosure” granted by the Securities Analysts Association of Japan (SAAJ) to promote the quality and fairness of corporate disclosure. This marks the eighth time Astellas has received this recognition.



2026 Award for Excellence in Corporate Disclosure

– Industries –



The Securities Analysts
Association of Japan

Astellas ranked first in four of the five evaluation categories. In particular, Astellas received higher scores than in the previous year in the categories of “Management’s Commitment to Investor Relations, Function of the IR Department, and Basic IR Stance” and “Disclosure of ESG-related Information,” which contributed significantly to its strong overall evaluation.

For details on the “2026 Award for Excellence in Corporate Disclosure,” please refer to [the website](#) of the SAAJ.

Naoki Okamura, President and CEO, Astellas

“To help stakeholders better understand its efforts to enhance corporate value, Astellas provides timely and appropriate disclosure of the value of our products and the results of clinical trials. For projects under research and development, we proactively communicate not only their unique features, but also the value they may bring to society after they are launched. We also engage with stakeholders to deepen their understanding of the growth strategy and approach to enhancing corporate value outlined in the Corporate Strategic Plan 2026. Furthermore, we strive to create*

opportunities to provide information flexibly in line with the needs of stakeholders so that we do not unilaterally disseminate information. We believe these efforts in disclosure and dialogue were recognized and led to this recognition. Astellas will continue to proactively engage in dialogue with stakeholders, aiming for proper market valuation, and strive to enhance and improve the quality of its disclosure.”

*For more information on Astellas Corporate Strategic Plan, please visit <https://www.astellas.com/en/about/corporate-strategic-plan>

About Astellas

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
+81-3-3244-3201
